About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...

One of the largest energy infrastructure companies is rolling out plans to expand a natural gas pipeline in the CSRA.

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth.

With a market cap of $153.4 billion, Amgen Inc. (AMGN) is a global leader in biotechnology, focusing on innovative human ...

“The Company's precision approach to immunology has delivered a pipeline of differentiated ... Mr. Danilkowicz joins Alumis from Amgen after serving as Senior Vice President, Commercial Strategy ...

The company, known for its innovative treatments in ophthalmology and immunology, has seen its stock performance fluctuate as it faces increasing competition and legal hurdles while also making ...